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Amyotrophic lateral sclerosis (ALS) may be associated with low body mass index (BMI) at the time of diagnosis.
However, the role of premorbid BMI in the development of ALS and survival after diagnosis remains unclear. In
2005–2010, we interviewed 467 patients with ALS from the US National Registry of Veterans with ALS and 975
frequency-matched veteran controls. In this sample, we evaluated the association of BMI and BMI change at differ-
ent ages with ALS risk using unconditional logistic models and with survival after ALS diagnosis using Cox propor-
tional hazards models. After adjustment for confounders, compared with a moderate increase in BMI between ages
25 and 40 years, stable or decreasing BMI was positively associated with ALS risk (odds ratio (OR) = 1.61, 95%
confidence interval (CI): 1.20, 2.16). A 1-unit increase in BMI at age 40 years (OR = 0.95, 95% CI: 0.91, 0.98) but
not at age 25 years (OR = 0.99, 95% CI: 0.95, 1.03) was inversely associated with ALS. These associations were
similar for bulbar and spinal ALS but stronger for those with a delay of less than 1 year between symptom onset
and diagnosis. We found no association between prediagnosis BMI and survival. A decreasing BMI from early to
middle age and a low BMI in middle age may be positively associated with ALS risk.
amyotrophic lateral sclerosis; body mass index; body weight changes; United States
Abbreviations: ALS, amyotrophic lateral sclerosis; BMI, body mass index; CI, confidence interval; GENEVA, Genes and
Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; MSAS, minimum sufficient adjustment set; OR, odds
ratio; VA, Department of Veterans Affairs.
Amyotrophic lateral sclerosis (ALS) is a neurodegenera-
tive disease characterized by loss of motor neurons in the
brain and spinal cord (1). The disease leads to muscle weak-
ness in multiple regions of the body and often progresses
rapidly to death. Approximately 5%–10% of patients have a
family history of ALS, and mutations identified to date
account for up to 70% of familial cases (2). Conversely, the
etiology of sporadic ALS is largely unknown, although com-
plex interactions between external causes and genetic sus-
ceptibility are likely to be involved (3).
Hypermetabolism, together with abnormalities in lipid
and carbohydrate metabolism, is prevalent in patients with
ALS (4–6). Positive prognostic factors in patients with ALS
may include elevated triglyceride and cholesterol levels,
high subcutaneous fat, and a high-energy diet (7–10). Lower
body mass index (BMI) and faster reductions in BMI after
disease onset have been independently associated with
shorter ALS survival (11, 12). Whether premorbid BMI
and weight change are associated with ALS prognosis is
unknown.
Metabolic factors may be associated with ALS risk as
well as prognosis. In 2 cohort studies, higher ALS inci-
dence or mortality was associated with lower premorbid
BMI measured up to 28 years before symptom onset (13, 14).
However, the relationship between premorbid weight change
and ALS risk has rarely been examined.
Early adulthood and middle age may be important time
windows for neurodegeneration, as suggested for Parkinson
disease (15). Therefore, we studied the association of premor-
bid BMI and BMI change with ALS risk and survival in a
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sample of US military veterans, focusing on young adulthood
(age 25 years) and middle age (age 40 years).
METHODS
Study design
The Genes and Environmental Exposures in Veterans with
Amyotrophic Lateral Sclerosis (GENEVA) Study is a case-
control study that enrolled cases from the National Registry
of Veterans with ALS, established by the Department of
Veterans Affairs (VA), and a representative sample of vet-
eran controls (16). Using data from GENEVA, we conducted
a case-control analysis to compare self-reported BMIs at spe-
cific ages in individuals who developed ALS with those of
matched controls. To assess the association of BMI with
ALS survival, we followed cases prospectively until death
or administrative censoring. Institutional review boards at
the Durham Veterans Administration Medical Center, Duke
University Medical Center, and the National Institute of
Environmental Health Sciences approved the study, and all
participants provided informed written or oral consent.
Study participants and outcome definitions
The Durham Veterans Administration Medical Center
enrolled individuals with motor neuron diseases in the VA
Registry between April 1, 2003, and September 30, 2007
(17). Neurologists specializing in motor neuron diseases used
information from medical records to assign a diagnosis ac-
cording to a formal algorithm based on the World Federation
of Neurology’s revised El Escorial ALS diagnostic criteria
(18). The VA Registry included patients diagnosed with
ALS (definite, probable, or possible), lower motor neuron
disease (suspected ALS), or primary lateral sclerosis. Patients
were interviewed by telephone every 6 months to monitor
disease progression (clinical interview).
GENEVA included a subset of ALS patients from the
VA Registry. The present analysis excluded patients with
primary lateral sclerosis (which generally does not progress
to ALS) (n = 39), patients with lower motor neuron disease
(n = 114), and patients with possible ALS (n = 48), leav-
ing 469 cases with definite or probable ALS. One of these
patients was diagnosed with a defined pathogenic mutation
according to the medical records. Because prediagnosis
weight before age 25 years was not ascertained, we excluded
2 participants who were less than 25 years of age at their
ALS diagnosis, leaving 467 cases for analysis.
Veteran controls (n = 975) were identified from the
Beneficiary Identification and Records Locator Subsystem
database maintained by the VA (16). From an age-stratified
random sample of 10,000 veterans, controls were frequency-
matched to cases on age at the reference date (the date of
ALS diagnosis for cases and the date of interview for con-
trols) and on use of VA health care before the reference date.
The latter factor compensates for the possibility that veterans
with ALS might use VA health care more after diagnosis
because of the suspicion that the condition is related to mili-
tary service, while controls would lack such motivation. The
study sample reflects a 77% participation rate among patients
and a 63% participation rate among controls.
Clinical information—such as site of symptom onset
(bulbar, if difficulties in speaking or swallowing, or spinal,
if limb symptoms) and diagnostic delay (time between
symptom onset and diagnosis)—was available from partici-
pants’ medical records and was used to group patients with
ALS. Birth and diagnosis dates were used to compute age
at ALS diagnosis (years). We extracted dates of death
through July 2013 from the Austin Vital Status File, which
has been validated against the National Death Index (19).
Exposure and covariates
We collected information retrospectively in a structured
telephone interview conducted with GENEVA participants or
their proxies; proxies were interviewed for 30 ALS cases and
no controls. We interviewed participants with ALS an aver-
age of 4 years after they were diagnosed. We collected infor-
mation on weight at age 25 years, at age 40 years, and at the
reference date, as well as information on height at age 25
years and at the reference date. We chose ages 25 and 40
years a priori to represent young adulthood and middle age.
We calculated BMI (weight (kg)/height (m)²) at age 25 years
and at the reference date from the self-reported weights and
heights at those ages, respectively (20). Because information
on height at age 40 years was not collected, BMI for that age
was calculated using height at age 25 years and only if the
participant’s age at the reference date was at least 40 years.
BMI values of ≤15 or ≥55 were considered unlikely and set
to missing. BMI was considered as a continuous or categori-
cal variable (lean: <20; normal weight: 20–<25; overweight:
25–<30; obese: ≥30). BMI change was defined as the differ-
ence in BMI between 2 time points and was considered as
either a continuous or categorical variable (based on the in-
terquartile range of change in BMI between ages 25 and 40
years: decrease or stable: <0.5; moderate increase: 0.5–<3.5;
substantial increase: ≥3.5).
We constructed directed acyclic graphs to identify con-
founders and minimum sufficient adjustment sets (MSASs)
for the association of BMI at different ages or BMI change
with ALS risk or survival (21).
ALS risk. In addition to the matching variables, we con-
sidered other potential confounders (collected in the tele-
phone interview) for the association between BMI measures
and ALS risk. These potential confounders included sex,
race/ethnicity (non-Hispanic white, other), smoking (never or
ever smoked at least 1 cigarette/day before reference date),
education (5–12, 13–16, 17–20, or 21–35 years), and birth
date as an indicator of cohort effects. Our proposed directed
acyclic graph suggested an MSAS for BMI (at any age) that
included age, use of VA health care, sex, race/ethnicity, smok-
ing, and education (see Web Figure 1, available at http://aje.
oxfordjournals.org/). We also carefully considered alternative
directed acyclic graphs that included more variables, such as
variables related to military service.
ALS survival. Potential confounders for the association
between BMI measures and ALS survival also included
length of diagnostic delay (days) as a measure of disease pro-
gression, site of symptom onset, and use of riluzole (the only
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drug approved for the treatment of ALS) (22). Use of riluzole
was ascertained in the clinical interviews conducted through
September 2009 to monitor the health status of patients. For
survival, the MSAS included birth date and diagnostic delay
for prediagnosis BMI, and it included age at diagnosis, diag-
nostic delay, riluzole use, and symptom onset site for BMI at
diagnosis (Web Figure 1). We defined use of riluzole (yes,
no) by using information from the clinical interview closest
to the date of GENEVA enrollment.
Statistical analyses
ALS risk. We compared distributions of BMI variables
and covariates between cases and controls using the χ2 test
or Wilcoxon rank-sum test, depending on the nature of the
variable. We used unconditional logistic regression to esti-
mate odds ratios and 95% confidence intervals for associa-
tions between ALS risk and BMI at different ages and BMI
change between ages. We used multinomial logistic regres-
sion and likelihood ratio tests to study whether the associa-
tion of BMI with ALS varied by site of symptom onset
(spinal, bulbar) or diagnostic delay (short: ≤1 year; moder-
ate: >1–≤3 years; long: >3 years). To assess whether high
BMI or BMI change was associated with delayed ALS
onset, we tested the association between BMI measures
and age at ALS diagnosis using linear regression.
ALS survival. We employed Cox regression analysis to
estimate hazard ratios and 95% confidence intervals for asso-
ciations between survival and BMI measures among patients
with ALS. The time scale of interest was time (days) since
ALS diagnosis. Patients entered the risk set at the date of
the GENEVA interview and were followed until death or
July 2013, whichever came first. To properly account for
left-truncation, we excluded the time interval before the
completion of the GENEVA interview from the time at
risk, since patients had to remain alive until the interview
to be eligible. The assumption of proportional hazards was
assessed using Schoenfeld residuals.
For both risk and survival, we estimated measures of
association for each unit increase in BMI (or BMI change)
by using continuous BMI (or BMI change). We used within-
category median values to create a predictor variable for test-
ing trends. Mutual adjustment and stratification were used to
investigate the independence of the associations of BMI
change across different ages and the respective attained BMI
with ALS risk and survival. Analyses stratified by sex and
race/ethnicity were conducted if the sample size of the sub-
groups was sufficiently large.
We conducted a sensitivity analysis restricted to cases
diagnosed within 2 years before the GENEVA interview
because long-surviving patients are potentially overrepre-
sented in GENEVA. Similarly, to address the possibility that
the presence of undiagnosed ALS could account for partici-
pants with ALS having lower BMIs than control participants
at age 40 years, we conducted an analysis restricted to partici-
pants with an age at the reference date of more than 45 years,
assuming that patients with ALS would be free of symptoms
5 or more years before diagnosis.
We used STATA, version 12.1 (StataCorp LP, College
Station, Texas), for statistical analyses.
RESULTS
ALS risk
Compared with controls, patients with ALS were more
likely to be male, non-Hispanic white, and less educated
(Table 1). Cases and controls were on average 59 years of age,
and 94% were aged 40 years or older at the reference date.
After adjustment for age, use of VA health care, sex, and
race/ethnicity, ALS was not associated with BMI at age 25
years, but it was inversely associated with BMI both at age
40 years and at the reference date (Table 2). Further adjust-
ment for smoking and education (the suggested MSAS) pro-
duced similar estimates. The presence of missing values for
the covariates was independent of BMI (P > 0.05).
The correlation between BMI at age 25 years and BMI at
age 40 years was 0.70. BMI change between ages 25 and 40
years was inversely associated with ALS; a stable or decreas-
ing BMI between ages 25 and 40 years was associated with
60% higher odds of ALS compared with a moderate increase,
but we saw no change in odds between substantial and moder-
ate increases in BMI (Table 3). BMI change between age 40
years and the reference date was also inversely associated with
ALS after adjustment for the MSAS plus BMI at the reference
date (odds ratio (OR) = 0.94, 95% confidence interval (CI):
0.89, 0.98). The association of ALS risk with BMI change was
constant across categories of BMI; similarly, the association of
ALS risk with BMI was constant across categories of BMI
change (data not shown).
Age at diagnosis was independent of prediagnosis BMI
at age 25 years (average increase in years per 1-unit
increase in BMI = 0.07, 95% CI: −0.08, 0.22) and at age
40 years (average increase = 0.08, 95% CI: −0.05, 0.21) or
BMI change between ages 25 and 40 years (average
increase = 0.09, 95% CI: −0.09, 0.27) after adjustment for
birth date, sex, race/ethnicity, use of VA health care, smoking
status, and education.
The association between BMI at age 40 years and ALS
did not vary with symptom onset site, but it appeared stron-
gest among patients with a short diagnostic delay (Tables 4
and 5). Similar patterns were noted for BMI at age 25 years
and at the reference date (Web Tables 1 and 2).
The results were similar after restricting the analysis to
men (for BMI at age 40 years, MSAS-adjusted OR = 0.95,
95% CI: 0.92, 0.99) and to non-Hispanic white men (for
BMI at age 40 years, MSAS-adjusted OR = 0.95, 95% CI:
0.91, 0.98). The number of women and participants of
other races/ethnicities was too low to analyze these sub-
groups separately (Table 1).
The exclusion of 273 cases that were diagnosed 2 or more
years before the GENEVA interview left results largely
unchanged (for BMI at age 40 years, MSAS-adjusted OR =
0.97, 95% CI: 0.93, 1.02). Therefore, these associations are
not unique to long-surviving patients. Furthermore, after
excluding 44 controls and 27 cases with an age at the refer-
ence date of less than 45 years, none of the cases included
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had symptom onset before age 40 years, and the MSAS-
adjusted odds ratio for BMI at age 40 years remained 0.96
(95% CI: 0.92, 0.99), suggesting that the effect of symptom-
atic ALS on BMI is unlikely to explain the association
between BMI at age 40 years and ALS.
We found no evidence for confounding due to factors
related to military service after additionally adjusting for
years of service, years of deployment, and role in the mili-
tary (officer vs. enlisted) (data not shown).
ALS survival
After excluding 7 patients who had died before their proxies
were interviewed, the median follow-up time for the patients
(time between interview and death or censoring) was 2 years
(interquartile range, 1–6 years). Among the 333 patients who
died during follow-up (72%), the median survival from diag-
nosis was 4 years (interquartile range, 2–6 years).
Higher BMI at diagnosis, but not at age 40 years, was
associated with longer survival (Table 6). A greater increase
in BMI between age 40 years and diagnosis was also associ-
ated with longer survival (hazard ratio = 0.92, 95% CI: 0.88,
0.97; adjusted for the MSAS plus BMI at diagnosis). We
found no association with ALS survival for either BMI at
age 25 years (MSAS-adjusted hazard ratio = 1.00, 95% CI:
0.96, 1.04) or BMI change between ages 25 and 40 years
(MSAS-adjusted hazard ratio = 1.03, 95% CI: 0.98, 1.08).
The proportional hazards assumption was met for all mea-
sures of BMI except for categories of BMI at diagnosis, and
we cannot exclude the possibility that the association of BMI
at diagnosis with survival changes over time.
DISCUSSION
We found that individuals with a stable or decreasing
BMI between ages 25 and 40 years were at significantly
Table 1. Characteristics of Veterans Included in the Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis
Study, United States, 2005–2010
Characteristic
Controls (n = 975) ALS Casesa (n = 467)
P Valueb
Median (IQR) No. % Median (IQR) No. %
BMI at age 25 yearsc 23.7 (21.7–25.2) 23.6 (21.7–25.5) 0.727
BMI at age 40 years 25.8 (23.8–28.0) 25.2 (23.1–27.8) 0.020
BMI at reference date 27.7 (25.2–31.0) 26.4 (23.8–29.0) <0.001
Age at reference date, years 60 (53–68) 60 (53–67) 0.510
Years between reference date and interview 0.0 (0.0–0.0) 2.5 (1.3–4.8)
Sex <0.001
Male 907 93.0 456 97.6
Female 68 7.0 11 2.4
Race/ethnicity 0.004
Non-Hispanic white 847 86.9 430 92.1
Other 128 13.1 37 7.9
Use of VA health care 0.613
Never use before reference date 571 58.7 280 60.1
Ever use before reference date 402 41.3 186 39.9
Missing 2 1
Education before reference date, years <0.001
5–12 210 21.7 143 30.8
13–16 494 51.0 227 48.8
17–20 216 22.3 87 18.7
21–35 49 5.1 8 1.7
Missing 6 2
Cigarette smoking (≥1 cigarette/day) 0.998
Never smoking before reference date 358 37.2 168 37.2
Ever smoking before reference date 605 62.8 284 62.8
Missing 12 15
Abbreviations: ALS, amyotrophic lateral sclerosis; BMI, body mass index; IQR, interquartile range; VA, Department of Veterans Affairs.
a Diagnosed as having clinically definite or clinically probable ALS.
b P value from Wilcoxon rank-sum test (continuous variables) or χ2 test (categorical variables).
c BMI was calculated as weight (kg)/height (m)2.
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higher risk of ALS compared with those who gained
weight while aging. We also found an inverse relationship
between prediagnosis BMI in middle age (40 years) and
ALS risk. In addition, we found a higher BMI at ALS diag-
nosis and increases in BMI between age 40 years and diag-
nosis to be associated with longer ALS survival. However,
prediagnosis BMI and BMI change before age 40 years
were not associated with survival.
Low premorbid BMI has previously been suggested to
be a risk factor for ALS (23). We found no association of
ALS with BMI at age 25 years, but the underrepresentation
of overweight and obese groups among military personnel
at that age could have minimized the real association.
Nevertheless, the inverse association between BMI at age
40 years and ALS is similar to that reported in a previous
meta-analysis, which found a relative rate of ALS of 0.79
(95% CI: 0.73, 0.86) per 5-unit increase in premorbid BMI
(14). An association of premorbid BMI and BMI change
with ALS is consistent with a study by Dupuis et al. (24),
which found that superoxide dismutase 1 (SOD1)-mutant
mice had reduced adipose tissue accumulation and
increased energy expenditure weeks before symptom onset.
We found that the association between BMI and ALS risk
was stronger for ALS with a short diagnostic delay and
that individuals with low BMI had a shorter diagnostic
delay. This result may be due to individuals with low BMI
Table 2. Associations of Body Mass Index at Age 25 Years, Age 40 Years, and the Reference Date With the Risk of Amyotrophic Lateral
Sclerosis, Genes and Environmental Exposures in Veterans With Amyotrophic Lateral Sclerosis Study, United States, 2005–2010
Variable
Controls ALS Cases Model 1a Model 2b
No. % No. % OR 95% CI OR 95% CI
BMI at age 25 yearsc,d 972 100.0 454 100.0 0.99 0.95, 1.03 0.99 0.95, 1.03
Category of BMI at age 25 years
15–<20 88 9.0 36 7.9 0.96 0.63, 1.46 0.88 0.57, 1.35
20–<25 581 59.8 265 58.4 1.00 Referent 1.00 Referent
25–<30 269 27.7 141 31.1 1.08 0.83, 1.39 1.07 0.82, 1.38
≥30.0 34 3.5 12 2.6 0.73 0.37, 1.45 0.71 0.36, 1.42
P for linear trende 0.969 0.930
Missing 3 13
BMI at age 40 yearsd 914 100.0 421 100.0 0.95 0.91, 0.98 0.95 0.91, 0.98
Category of BMI at age 40 years
15–<20 17 1.9 8 1.9 0.95 0.40, 2.26 0.92 0.38, 2.22
20–<25 346 37.9 177 42.0 1.00 Referent 1.00 Referent
25–<30 435 47.6 199 47.3 0.84 0.65, 1.08 0.85 0.65, 1.10
≥30.0 116 12.7 37 8.8 0.59 0.39, 0.90 0.60 0.39, 0.92
P for linear trende 0.015 0.021
Missing 7 13
BMI at reference dated 974 100.0 466 100.0 0.90 0.88, 0.93 0.90 0.88, 0.93
Category of BMI at reference date
15–<20 8 0.8 13 2.8 2.27 0.90, 5.71 2.21 0.87, 5.66
20–<25 204 21.0 152 32.6 1.00 Referent 1.00 Referent
25–<30 441 45.3 217 46.6 0.63 0.48, 0.83 0.66 0.50, 0.87
≥30.0 321 33.0 84 18.0 0.34 0.24, 0.47 0.35 0.25, 0.49
P for linear trende <0.001 <0.001
Missing 1 1
Abbreviations: ALS, amyotrophic lateral sclerosis; BMI, body mass index; CI, confidence interval; OR, odds ratio.
a Odds ratios were adjusted for age, sex, race/ethnicity, and use of the Department of Veterans Affairs system for health care. Because of
missing values in the covariates, 1 case and 2 controls were excluded from the model for BMI at age 25 years, age 40 years, and the reference
date.
b Odds ratios were adjusted for age, sex, race/ethnicity, use of the Department of Veterans Affairs system for health care, cigarette smoking,
and years of education. Because of missing values in the covariates, 17 cases and 20 controls were excluded from the model for BMI at age
25 years and the reference date, and 16 cases and 18 controls were excluded from the model for BMI at age 40 years.
c BMI was calculated as weight (kg)/height (m)2.
d Odds ratio for ALS for a 1-unit increase in BMI.
e The within-category median BMI was assigned to each observation, and this new variable was used as a predictor variable for testing the
trend.
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Table 3. Association of Change in Body Mass Index Between Ages 25 and 40 Years With the Risk of
Amyotrophic Lateral Sclerosis, Genes and Environmental Exposures in Veterans With Amyotrophic Lateral
Sclerosis Study, United States, 2005–2010
Variable
Controls ALS Cases Model 1a Model 2b
No. % No. % OR 95% CI OR 95% CI
BMI changec,d 913 100.0 418 100.0 0.94 0.89, 1.00 0.94 0.89, 1.00
Category of change in BMIe
Decrease or stable 188 20.6 128 30.6 1.61 1.21, 2.14 1.61 1.20, 2.16
Moderate increase 473 51.8 194 46.4 1.00 Referent 1.00 Referent
Substantial increase 252 27.6 96 23.0 1.06 0.77, 1.45 1.06 0.76, 1.47
P for linear trendf 0.088 0.093
Missing 8 16
Abbreviations: ALS, amyotrophic lateral sclerosis; BMI, body mass index; CI, confidence interval; OR, odds ratio.
a Odds ratios were adjusted for age at the reference date, use of the Department of Veterans Affairs system for
health care, and BMI at age 40 years; 1 case and 2 controls were excluded from the model because of missing va-
lues in the covariates.
b Odds ratios were adjusted for age, use of the Department of Veterans Affairs system for health care, BMI at age
40 years, cigarette smoking, and years of education; 16 cases and 18 controls were excluded from the model because
of missing values in the covariates.
c BMI was calculated as weight (kg)/height (m)2.
d Odds ratio for ALS for a 1-unit increase in BMI change.
e Based on the interquartile range of change in BMI between ages 25 and 40 years: decrease or stable: <0.5;
moderate increase: 0.5–<3.5; substantial increase: ≥3.5.
f The within-category median BMI change was assigned to each observation, and this new variable was used as a
predictor variable for testing the trend.
Table 4. Association of Body Mass Index at Age 40 Years With Amyotrophic Lateral Sclerosis According to Site
of Symptom Onset, Genes and Environmental Exposures in Veterans With Amyotrophic Lateral Sclerosis Study,
United States, 2005–2010
Variable




a 95% CI No. ofCases % OR
a 95% CI
BMI at age 40 yearsb,c 341 100.0 0.95 0.92, 0.99 60 100.0 0.93 0.85, 1.01
Category of BMI at age 40 years
15–<20 7 2.0 1.02 0.41, 2.55 1 1.7 0.76 0.10, 6.05
20–<25 139 40.8 1.00 Referent 28 46.7 1.00 Referent
25–<30 161 47.2 0.85 0.64, 1.12 29 48.3 0.93 0.53, 1.65
≥30.0 34 10.0 0.68 0.44, 1.07 2 3.3 0.25 0.06, 1.10
P for linear trendd 0.107 0.140
Missing 9 3
P for combining spinal- and
bulbar-onset ALSe
0.285
Abbreviations: ALS, amyotrophic lateral sclerosis; BMI, body mass index; CI, confidence interval; OR, odds ratio.
a Odds ratios for the association of BMI with bulbar or spinal ALS versus no ALS. Estimates were adjusted for age,
sex, race/ethnicity, use of the Department of Veterans Affairs system for health care, cigarette smoking, and years of
education; 16 cases and 18 controls were excluded from the model because of missing values in the covariates.
b BMI was calculated as weight (kg)/height (m)2.
c Odds ratio for ALS for a 1-unit increase in BMI.
d The within-category median BMI was assigned to each observation, and this new variable was used as a pre-
dictor variable for testing the trend.
e P value from likelihood ratio tests of whether the 2 types could be combined.
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being diagnosed sooner rather than having a faster progres-
sion rate. In fact, we did not find an association between
prediagnosis BMI and ALS survival; only BMI at diagno-
sis and BMI change between age 40 years and diagnosis
were associated with ALS survival. Other studies support
the hypothesis that BMI change immediately before ALS
diagnosis is both a common feature of ALS and a prognos-
tic factor, whereas evidence that BMI at ALS diagnosis is a
prognostic factor is inconsistent, possibly due to small sam-
ple sizes in some studies (12, 25–27).
Research on fat metabolism and ALS is sparse, and the
mechanisms underlying hypermetabolism in ALS are currently
unclear (10). However, many of the main ALS genes are
related to energy metabolism to some extent. Dyslipidemia,
reduced adipose tissue accumulation, and increased resting
energy expenditure are typical features of the SOD1-mutant
ALS mice in the presymptomatic phase (24, 28). Moreover,
mice lacking TAR DNA-binding protein 43 (TDP-43),
which is pathologically altered in ALS, had rapid loss of
body fat and down-regulation of TBC1 domain family mem-
ber 1 (TBC1D1), a gene linked to human obesity (29–31).
RNA/DNA-binding fused in sarcoma (FUS), another protein
important for RNA metabolism that has been linked to ALS,
interacts with key proteins in energy metabolism (32). Interest-
ingly, mutations affecting TDP-43 and FUS are uncommon in
patients with ALS and co-occurring frontotemporal dementia
that have higher BMI compared with patients without cogni-
tive symptoms (33, 34). The most commonly mutated gene in
ALS known to date is chromosome 9 open reading frame
72 (C9ORF72), which encodes a protein of still uncharacter-
ized function (35). Nevertheless, C9ORF72 repeat expansions
in a mouse model were associated with TDP-43 pathology,
decreased body weight, and hyperactivity (36).
Whether metabolic features are risk factors for ALS or
rather prodromal symptoms of the disease remains unclear.
ALS may have a long presymptomatic period similar to that
observed for Alzheimer and Parkinson diseases (37). Although
we cannot address this question, our study provides evidence
that patients with ALS may have altered BMI long before the
onset of motor symptoms. Availability of energy reserves in
individuals with normal or high BMI might both provide pro-
tection from neurotoxic exposures and retard the development
and progression of symptoms by mitigating the increased
energy requirements associated with ALS. Furthermore, low
BMI might be an early and maybe lifelong feature of the dis-
ease that is suggestive of an underlying disease process leading
to clinically manifest ALS years later. Metabolic dysfunction,
especially hyperlipidemia, is known to predict disease progres-
sion and prognosis, but a better understanding of the role and
timing of metabolic changes occurring before motor symptoms
is needed to determine whether the association between BMI
and ALS is due to reverse causation (38, 39).
Table 5. Association of Body Mass Index at Age 40 Years With Amyotrophic Lateral Sclerosis According to Diagnostic Delay, Genes and
Environmental Exposures in Veterans With Amyotrophic Lateral Sclerosis Study, United States, 2005–2010
Variable
ALS Diagnostic Delay
Short (≤1 Year) Moderate (>1–≤3 Years) Long (>3 Years)
No. of
Cases % OR
a 95% CI No. ofCases % OR
a 95% CI No. ofCases % OR
a 95% CI
BMI at age 40 yearsb,c 189 100.0 0.91 0.87, 0.96 147 100.0 0.96 0.91, 1.02 70 100.0 1.01 0.95, 1.09
Category of BMI at age 40
years
15–<20 5 2.7 1.22 0.43, 3.46 1 0.7 0.36 0.05, 2.77 2 2.9 1.60 0.34, 7.45
20–<25 87 46.0 1.00 Referent 58 39.5 1.00 Referent 23 32.9 1.00 Referent
25–<30 83 43.9 0.72 0.51, 1.02 73 49.7 0.89 0.60, 1.32 38 54.3 1.38 0.80, 2.38
≥30.0 14 7.4 0.44 0.23, 0.81 15 10.2 0.78 0.41, 1.45 7 10.0 0.92 0.38, 2.25
P for linear trendd 0.003 0.586 0.948
Missing 9 2 1
P for combining short and
moderate delayse
0.459
P for combining short and
long delayse
0.094
P for combining moderate
and long delayse
0.388
Abbreviations: ALS, amyotrophic lateral sclerosis; BMI, body mass index; CI, confidence interval; OR, odds ratio.
a Odds ratios for the association of BMI with ALS with short, moderate, and long diagnostic delays versus no ALS. Estimates were adjusted
for age, sex, race/ethnicity, use of the Department of Veterans Affairs system for health care, cigarette smoking, and years of education; 16
cases and 18 controls were excluded from the model because of missing values in the covariates.
b BMI was calculated as weight (kg)/height (m)2.
c Odds ratio for ALS for a 1-unit increase in BMI.
d The within-category median BMI was assigned to each observation, and this new variable was used as a predictor variable for testing the trend.
e P value from likelihood ratio tests of whether the 2 outcomes could be combined.
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Our results should be interpreted cautiously because BMI
fails to discriminate between very muscular individuals and
overweight individuals (40). Nevertheless, both BMI and
waist-to-hip ratio—but not height and hip circumference—
were found to be inversely associated with ALS mortality (13).
Our study had several limitations. First, self-reporting of
weight and height may have produced misclassification of
BMI. Our results would overestimate the real association
between BMI at age 40 years and ALS risk if persons with
ALS underestimated their weight at age 40 years compared
with controls, for example if current BMI affects the recall
of previous BMI.
Second, controls in our study might have only imperfectly
represented the underlying population giving rise to the ALS
cases. Controls were on average more educated than both the
general population of US military veterans and the GENEVA
ALS cases (16). Adjusting for education did not, however,
change the association between BMI and ALS observed
in the present study. Further, because educational level is
inversely associated with BMI in the US population, it is
possible that controls were thinner than the general popula-
tion of US veterans and that the inverse association between
BMI and ALS was underestimated in our study (41).
Third, the data we used for the survival analyses were left-
truncated because only patients with ALS who survived until
the time of interview were included. Therefore, the propor-
tion of patients with a long disease duration might be higher
in GENEVA than in the entire population of US military
veterans. The association of ALS with BMI at age 40 years,
however, changed only slightly after exclusion of patients
diagnosed at least 2 years before the interview.
Finally, our sample of US military veterans—which con-
sisted mostly of non-Hispanic white men—may not repre-
sent other populations of ALS patients and healthy
controls. Veterans might have had different environmental
exposures than nonmilitary populations. Although expo-
sure to toxic agents has been found to be associated with
risk of ALS among military personnel, it is not very likely
that the associations between BMI and ALS would be con-
founded by exposures specifically associated with military
service, because these risk factors for ALS do not strongly
affect BMI (42). If any residual confounding is present, it
could arise from the imperfect adjustment for smoking and
lack of detailed information on physical activity (43).
However, information on smoking duration, cigarette pack-
years, and participation in organized sport was available,
Table 6. Associations of Body Mass Index at Age 40 Years and Body Mass Index at Diagnosis Date With Survival After Amyotrophic Lateral
Sclerosis Diagnosis, Genes and Environmental Exposures in Veterans With Amyotrophic Lateral Sclerosis Study, United States, 2005–2013









HRa 95% CI HRb 95% CI
BMI at age 40 yearsc,d 415 100.0 308 100.0 1 330.7 1.01 0.97, 1.04 1.02 0.98, 1.05
Category of BMI at age
40 years
15–<20 7 1.7 6 1.9 30.0 1.39 0.61, 3.19 1.36 0.60, 3.12
20–<25 175 42.2 127 41.2 551.6 1.00 Referent 1.00 Referent
25–<30 196 47.2 146 47.4 639.3 0.95 0.75, 1.21 0.98 0.77, 1.25
≥30.0 37 8.9 29 9.4 109.8 1.11 0.73, 1.67 1.22 0.81, 1.85
P for linear trende 0.961 0.686
Missing 12 10
BMI at diagnosisd 459 100.0 333 100.0 1 515.5 0.97 0.94, 1.00 0.98 0.95, 1.01
Category of BMI at diagnosis
15–<20 13 2.8 12 3.6 30.7 1.64 0.89, 3.04 1.63 0.88, 3.02
20–<25 148 32.2 108 32.4 467.6 1.00 Referent 1.00 Referent
25–<30 215 46.8 160 48.1 719.6 0.87 0.68, 1.11 0.90 0.70, 1.17
≥30.0 83 18.1 53 15.9 297.7 0.70 0.50, 0.97 0.76 0.54, 1.07
P for linear trende 0.008 0.035
Missing 1 0
Abbreviations: ALS, amyotrophic lateral sclerosis; BMI, body mass index; CI, confidence interval; HR, hazard ratio.
a Hazard ratio for death from ALS among cases (adjusted for age at diagnosis).
b Hazard ratio for death from ALS among cases according to BMI at age 40 years (adjusted for date of birth and diagnostic delay) or BMI at
ALS diagnosis date (adjusted for age at diagnosis, diagnostic delay, riluzole use, and symptom onset site); 10 and 25 subjects were excluded
from the models for BMI at age 40 years and at the diagnosis date, respectively, because of missing values in the covariates.
c BMI was calculated as weight (kg)/height (m)2.
d Hazard ratio for ALS death for a 1-unit increase in BMI.
e The within-category median BMI was assigned to each observation, and this new variable was used as a predictor variable for testing the trend.
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and there was no association of ALS risk with these factors
in GENEVA (44).
Characteristics of our study population that were not a
consequence of military service, such as the sex distribu-
tion or the racial/ethnic and genetic background of partici-
pants, may affect the generalizability of our results.
Sex differences in the association between BMI and
ALS have previously been suggested and—although our
estimates were similar in the entire sample, in men, and in
non-Hispanic white men—our study lacked the statistical
power to study the associations among women or other eth-
nic groups (13). Nevertheless, our results were consistent
with published findings from different populations (12, 13).
Strengths of our study include the large sample size,
medical record–confirmed ALS diagnosis, detailed infor-
mation on covariates and clinical features, and information
on BMI at different ages. The latter enabled us to analyze
BMI and BMI change at younger ages.
In conclusion, a low BMI in middle age and a BMI that
did not increase before middle age may be associated with
a higher ALS risk later in life but not with ALS survival.
Further investigation of ALS risk and prediagnosis meta-
bolic features at younger ages is needed to better under-
stand our findings.
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